GlassScriptPhysician profile
Kyla Berrier
NPI 1346690666
$640.39
in general payments reported to CMS, 2019-2025
14 companies · $112 in 2025
The $112 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.91 · 2022: $170 · 2023: $199 · 2024: $79.62 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $140.23 | 2021-2025 | Vaxneuvance, Rotateq, Vaxelis |
| Ironshore Pharmaceuticals INC. | $127.36 | 2022-2023 | Jornay Pm |
| Corium, LLC | $62.82 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $60.76 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $57.79 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $32.50 | 2023-2024 | |
| Tris Pharma INC | $31.88 | 2022-2025 | Onyda Xr |
| Neos Therapeutics, LP | $29.92 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.04 | 2025 | Alvesco |
| Avion Pharmaceuticals | $17.38 | 2023 | Methylphenidate Hydrochloride |
| Glaxosmithkline, LLC. | $15.44 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.94 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $13.21 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.12 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Berrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.